PASG:NASDAQPassage Bio, Inc. Analysis

Technical indicators show PASG trading below its 20‑day (≈8.60), 50‑day (≈8.39) and 200‑day (≈8.66) moving averages, with a RSI of 36.8 that hints at oversold conditions yet remains above the extreme zone. The MACD is bearish (negative line, positive signal) and the price sits just above the identified support level of $5.75, while the nearest resistance sits near $12.05. Volatility is extreme at over 220% on a 30‑day basis and the computed beta of 3.15 signals a stock that swings far more than the market. Fundamentally, the company has zero revenue, a negative EBITDA of $‑42.4 M, and a cash balance of $46.3 M that modestly exceeds its $24.0 M debt, resulting in a high debt‑to‑equity ratio (>128%). The price‑to‑book of ~1.0 reflects a market that values the firm roughly at its book, but with no earnings and a trailing PE of zero, valuation metrics are largely meaningless at this stage.
Catalysts include recent positive data from the PBFT02 program, which showed improvements in disease‑progression biomarkers and reduced brain atrophy, lending credibility to the pipeline. Analysts (6) have a “buy” consensus with a median price target of $9.5 and a mean target of $12, implying upside potential of roughly 100% despite the “Extreme Greed” market sentiment (fear‑greed index 86.55). The combination of a low current price, a broad CNS‑focused pipeline, and strategic collaborations suggests upside, but the company’s cash burn, lack of revenue, and high systematic risk keep the risk profile elevated.